Guideline recommendations for cangrelor should be upgraded: pros and cons

EuroIntervention. 2024 Apr 1;20(7):e405-e407. doi: 10.4244/EIJ-E-23-00070.

Authors

George Dangas¹, Johny Nicolas¹, Paul Harbich², Kurt Huber^{2

3}

Affiliations

¹ Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² 3rd Department of Medicine, Cardiology and Intensive Care Unit, Clinic Ottakring (former Wilhelminenhospital), Vienna, Austria.
³ Sigmund Freud University, Medical Faculty, Vienna, Austria.

PMID: 38562067
PMCID: PMC10979382 (available on 2025-04-01)
DOI: 10.4244/EIJ-E-23-00070

No abstract available

MeSH terms

Adenosine Monophosphate / analogs & derivatives*
Adenosine Monophosphate / therapeutic use
Decision Making*
Humans
Platelet Aggregation Inhibitors* / therapeutic use
Purinergic P2Y Receptor Antagonists
Surveys and Questionnaires

Substances

cangrelor
Adenosine Monophosphate
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists